BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 27814273)

  • 1. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
    Wu Z; Zhou L; Ding G; Cao L
    Cancer Biomark; 2017; 18(1):35-39. PubMed ID: 27814273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
    Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
    PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.
    Zhu Z; Xu Y; Du J; Tan J; Jiao H
    J Surg Oncol; 2014 Feb; 109(2):89-94. PubMed ID: 24166773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
    Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
    Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
    Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression.
    Cheng RF; Wang J; Zhang JY; Sun L; Zhao YR; Qiu ZQ; Sun BC; Sun Y
    Chin J Cancer; 2016 Jul; 35(1):64. PubMed ID: 27371108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma.
    Zhu ZM; Xu YF; Su QJ; Du JD; Tan XL; Tu YL; Tan JW; Jiao HB
    Mol Cell Biochem; 2014 Mar; 388(1-2):39-49. PubMed ID: 24242138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis.
    Zhuo M; Yuan C; Han T; Cui J; Jiao F; Wang L
    BMC Cancer; 2018 Oct; 18(1):1032. PubMed ID: 30352575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
    Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival.
    He D; Miao H; Xu Y; Xiong L; Wang Y; Xiang H; Zhang H; Zhang Z
    PLoS One; 2014; 9(11):e112930. PubMed ID: 25411783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I.
    Song B; Ji W; Guo S; Liu A; Jing W; Shao C; Li G; Jin G
    FEBS Lett; 2014 Nov; 588(23):4375-81. PubMed ID: 25315416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manganese superoxide dismutase expression is negatively associated with microRNA-301a in human pancreatic ductal adenocarcinoma.
    Pandit H; Zhang W; Li Y; Agle S; Li X; Li SP; Cui G; Li Y; Martin RC
    Cancer Gene Ther; 2015 Oct; 22(10):481-6. PubMed ID: 26384137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma.
    Bai Z; Sun J; Wang X; Wang H; Pei H; Zhang Z
    Oncol Rep; 2015 Aug; 34(2):595-602. PubMed ID: 26062664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
    Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
    Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.